Alison Templeton

4.3k total citations · 2 hit papers
14 papers, 2.9k citations indexed

About

Alison Templeton is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Infectious Diseases. According to data from OpenAlex, Alison Templeton has authored 14 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 3 papers in Infectious Diseases. Recurrent topics in Alison Templeton's work include Lung Cancer Treatments and Mutations (5 papers), Colorectal Cancer Treatments and Studies (4 papers) and SARS-CoV-2 and COVID-19 Research (3 papers). Alison Templeton is often cited by papers focused on Lung Cancer Treatments and Mutations (5 papers), Colorectal Cancer Treatments and Studies (4 papers) and SARS-CoV-2 and COVID-19 Research (3 papers). Alison Templeton collaborates with scholars based in United Kingdom, United States and China. Alison Templeton's co-authors include Tony Mok, Serban Ghiorghiu, Yi‐Long Wu, Vassiliki A. Papadimitrakopoulou, Helen Mann, Willemijn S.M.E. Theelen, Marcelo Marotti, Chee Khoon Lee, Suresh S. Ramalingam and Hiroaki Akamatsu and has published in prestigious journals such as New England Journal of Medicine, The Journal of Infectious Diseases and Annals of Oncology.

In The Last Decade

Alison Templeton

14 papers receiving 2.9k citations

Hit Papers

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive... 2016 2026 2019 2022 2016 2022 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
    2016 2.4k citations Tony Mok, Yi‐Long Wu et al. New England Journal of Medicine profile →
  2. Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial
    2022 127 citations Hugh Montgomery, Richard Hobbs et al. The Lancet Respiratory Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alison Templeton United Kingdom 7 2.4k 1.9k 759 681 145 14 2.9k
Jennifer Tursi Italy 14 2.5k 1.0× 2.1k 1.1× 841 1.1× 681 1.0× 109 0.8× 25 3.2k
Zofia Piotrowska United States 26 2.1k 0.9× 1.7k 0.9× 938 1.2× 541 0.8× 34 0.2× 122 2.6k
Alex Friedlaender Switzerland 28 1.1k 0.5× 1.5k 0.8× 711 0.9× 437 0.6× 106 0.7× 86 2.3k
Tomonori Hirashima Japan 31 1.9k 0.8× 1.7k 0.9× 543 0.7× 196 0.3× 100 0.7× 146 2.7k
Alan H. Bryce United States 26 1.3k 0.5× 1.0k 0.6× 642 0.8× 545 0.8× 78 0.5× 167 2.5k
Á. Artal Spain 20 2.5k 1.0× 3.2k 1.7× 878 1.2× 606 0.9× 39 0.3× 82 4.3k
Carmelo Tibaldi Italy 20 991 0.4× 1.5k 0.8× 604 0.8× 351 0.5× 34 0.2× 73 2.1k
Carlo Barone Italy 31 1.4k 0.6× 2.3k 1.2× 769 1.0× 495 0.7× 81 0.6× 130 3.6k
Katherine Liau United States 19 843 0.3× 1.1k 0.6× 861 1.1× 441 0.6× 37 0.3× 36 2.0k
Hiroshige Yoshioka Japan 37 3.6k 1.5× 3.2k 1.7× 940 1.2× 589 0.9× 19 0.1× 204 4.5k

Countries citing papers authored by Alison Templeton

Since Specialization
Citations

This map shows the geographic impact of Alison Templeton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alison Templeton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alison Templeton more than expected).

Fields of papers citing papers by Alison Templeton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alison Templeton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alison Templeton. The network helps show where Alison Templeton may publish in the future.

Co-authorship network of co-authors of Alison Templeton

This figure shows the co-authorship network connecting the top 25 collaborators of Alison Templeton. A scholar is included among the top collaborators of Alison Templeton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alison Templeton. Alison Templeton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Albayaty, Muna, Dennis Brooks, Rosalinda H. Arends, et al.. (2023). Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults. The Journal of Infectious Diseases. 227(10). 1153–1163. 11 indexed citations
2.
Hobbs, Richard, Hugh Montgomery, Francisco Padilla, et al.. (2023). Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial. Infectious Diseases and Therapy. 12(9). 2269–2287. 3 indexed citations
3.
Montgomery, Hugh, Richard Hobbs, Francisco Padilla, et al.. (2022). Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet Respiratory Medicine. 10(10). 985–996. 127 indexed citations breakdown →
4.
Mok, Tony, Yi‐Long Wu, M. Ahn, et al.. (2017). Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer. QUT ePrints (Queensland University of Technology). 290 indexed citations
5.
Lee, Chee Khoon, Silvia Novello, Anna Rydén, et al.. (2017). Patient-reported symptoms and impact of treatment with osimertinib vs chemotherapy for advanced non-small cell lung cancer. Annals of Oncology. 28. ii30–ii30. 1 indexed citations
6.
Papadimitrakopoulou, Vassiliki A., Yi‐Long Wu, Myung‐Ju Ahn, et al.. (2017). PL03.03: Randomized Phase III Study of Osimertinib vs Platinum-Pemetrexed for EGFR T790M-Positive Advanced NSCLC (AURA3). Journal of Thoracic Oncology. 12(1). S5–S6. 2 indexed citations
7.
Baumann, Michaël, Sourbha S. Dani, Damien Dietrich, et al.. (2017). Vitamin D levels in Swiss breast cancer survivors. The Breast. 32. S51–S51. 5 indexed citations
8.
Mok, Tony, Yi‐Long Wu, Myung‐Ju Ahn, et al.. (2016). Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer. New England Journal of Medicine. 376(7). 629–640. 2369 indexed citations breakdown →
9.
Wu, Yi‐Long, Vassiliki A. Papadimitrakopoulou, Serban Ghiorghiu, Alison Templeton, & Tony Mok. (2015). AURA3 Design: a Randomised, Phase III Study of Azd9291 Versus Second-Line Chemotherapy for Patients (PTS) with Egfr-Tki-Resistant (T790M) Advanced Non-Small Cell Lung Cancer. Annals of Oncology. 26. i29–i29. 7 indexed citations
10.
González-Guerrero, Juan Francisco, et al.. (2015). 1973 Epidermal growth factor receptor (EGFR) over-expression and outcomes in early breast cancer: A systematic review and meta-analysis. European Journal of Cancer. 51. S324–S325. 1 indexed citations
11.
Anguera, Geòrgia, Ariadna Tibau, Fernando Andrés‐Pretel, et al.. (2015). 1215 Role of cooperative groups and funding source in clinical studies that support approved therapy for breast cancer. European Journal of Cancer. 51. S176–S177. 1 indexed citations
12.
Hermanns, Thomas, Raj Satkunasivam, Peter J. Boström, et al.. (2014). 793 A multidisciplinary bladder cancer clinic delivers personalized care for complex bladder cancer patients. European Urology Supplements. 13(1). e793–e793. 3 indexed citations
13.
Templeton, Alison, et al.. (2008). Multilumen Central Venous Catheters Increase Risk for Catheter-Related Bloodstream Infection: Prospective Surveillance Study. Infection. 36(4). 322–327. 57 indexed citations
14.
Dyson, E.H., et al.. (1985). Plasma glutathione S-transferase measurements by radioimmunoassay: a sensitive index of hepatocellular damage in man. Clinica Chimica Acta. 146(1). 11–19. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jennifer Tursi Breakdown of academic impact, for papers by Zofia Piotrowska Breakdown of academic impact, for papers by Alex Friedlaender Breakdown of academic impact, for papers by Tomonori Hirashima Breakdown of academic impact, for papers by Alan H. Bryce Breakdown of academic impact, for papers by Á. Artal Breakdown of academic impact, for papers by Carmelo Tibaldi Breakdown of academic impact, for papers by Carlo Barone Breakdown of academic impact, for papers by Katherine Liau Breakdown of academic impact, for papers by Hiroshige Yoshioka
Rankless by CCL
2026